Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00MIN
|
|||
| Former ID |
DAP001247
|
|||
| Drug Name |
Propylthiouracil
|
|||
| Synonyms |
propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil; Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperthyroidism [ICD-11: 5A02] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antithyroid Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H10N2OS
|
|||
| Canonical SMILES |
CCCC1=CC(=O)NC(=S)N1
|
|||
| InChI |
1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)
|
|||
| InChIKey |
KNAHARQHSZJURB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51-52-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9772, 72466, 113849, 630519, 855783, 3133458, 5371778, 6405436, 7847628, 7980419, 8147858, 8149507, 9268267, 10321756, 10524876, 11112111, 11335443, 11360682, 11363770, 11366332, 11368894, 11372721, 11374142, 11377056, 11461654, 11466522, 11467642, 11485099, 11486044, 11489118, 11491546, 11492307, 11494690, 14772576, 17389748, 22389304, 24870375, 24898446, 25183806, 26611899, 26679369, 26747269, 26747270, 26751509, 46505181, 47365078, 47365079, 47885302, 47885303, 47959626
|
|||
| ChEBI ID |
CHEBI:8502
|
|||
| ADReCS Drug ID | BADD_D01869 | |||
| SuperDrug ATC ID |
H03BA02
|
|||
| SuperDrug CAS ID |
cas=000051525
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Iodothyronine deiodinase type I (DIO1) | Target Info | Inhibitor | [4] |
| Thyroid peroxidase (TPO) | Target Info | Inhibitor | [5], [6] | |
| BioCyc | Thyronamine and iodothyronamine metabolism | |||
| Thyroid hormone metabolism II (via conjugation and/or degradation) | ||||
| Thyroid hormone metabolism I (via deiodination) | ||||
| Thyroid hormone biosynthesis | ||||
| KEGG Pathway | Thyroid hormone signaling pathway | |||
| Tyrosine metabolism | ||||
| Metabolic pathways | ||||
| Thyroid hormone synthesis | ||||
| Autoimmune thyroid disease | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathwhiz Pathway | Thyroid hormone synthesis | |||
| Reactome | Thyroxine biosynthesis | |||
| WikiPathways | Selenium Metabolism and Selenoproteins | |||
| Metabolism of amino acids and derivatives | ||||
| Selenium Micronutrient Network | ||||
| Hematopoietic Stem Cell Differentiation | ||||
| Differentiation Pathway | ||||
| Thyroxine (Thyroid Hormone) Production | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6650). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006188. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1. | |||
| REF 5 | Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214. | |||
| REF 6 | Theoretical aspects of the treatment with antithyroid drugs. Ann Endocrinol (Paris). 1994;55(1):1-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.